An observational study in Glaucoma, sponsored by Democritus University of Thrace. Recruiting at 1 site in Greece. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-11.
Sponsored by Democritus University of Thrace · Observational
Primary Objective
To validate the artificial intelligence subsystem of the DDART medical device for the automated detection of lesions compatible with glaucoma in a random sample of retinal fundus photographs.
1,419 studies on the registry are indexed under Glaucoma; 223 are open to participants now.
This study's planned enrollment of 2,000 is above the median of 101 across 385 observational studies indexed under Glaucoma.
Browse Glaucoma studies →Democritus University of Thrace is the lead sponsor of 70 studies on the registry; 8 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Participants that are able to provide consent for their fundus photograph to be recorded
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Color retinal fundus photographs will be acquired from: Digital non-mydriatic fundus cameras.
Validation of the sensitivity and specificity of the artificial intelligence subsystem for AMD detection
Time frame: 1 year
Validation of the sensitivity and specificity of the artificial intelligence subsystem for diabetic retinopathy detection
Time frame: 1 year
Plan to share: Undecided
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Democritus University of Thrace